Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Syncona (SYNC) Share News

IN BRIEF: Syncona portfolio company sees "encouraging" early data

10th Jun 2022 14:42

Syncona Ltd - London-based investor in healthcare companies - Announces that its portfolio company, Autolus Therapeutics PLC, has published new clinical data across multiple programmes. Autolus reports "positive" early safety and efficacy data from Auto4 in patients with T cell lymphoma and "encouraging" early safety and efficacy data from Auto1/22 in paediatric acute lymphoblastic leukaemia. Read More

UK earnings, trading statements calendar - next 7 days

9th Jun 2022 15:55

Syncona invests USD54 million in SwanBio Therapeutics funding round

18th May 2022 13:01

(Alliance News) - Syncona Ltd said on Wednesday it invested USD54 million in neurological disorder-focused gene therapy company SwanBio Therapeutics' Series B financing round. Read More

TRADING UPDATES: Belluscura to raise GBP5 million; React buys

12th May 2022 19:45

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Syncona investee Freeline narrows quarterly loss as costs fall

11th May 2022 09:30

(Alliance News) - Healthcare company investor Syncona Ltd on Wednesday noted that its portfolio company Freeline Therapeutics PLC trimmed its loss for the first quarter of 2022. Read More

IN BRIEF: Syncona investee Achilles widens quarterly loss on costs

10th May 2022 14:26

Syncona Ltd - investor in healthcare companies - Notes investee company Achilles Therapeutics PLC posts widened loss amid rising research & development costs. Pretax loss in the quarter ended March 31 widens to USD17.3 million from USD13.8 million a year ago. Research & development costs surge to USD13.0 million from USD8.9 million, mainly due to increased activity in ongoing clinical trials. Cash and equivalents on March 31 fall to USD236.9 million from USD266.3 million as of December 31. "The company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the second half of 2024," Achilles says. Read More

IN BRIEF: Syncona's investee Autolus widens quarterly loss as costs up

5th May 2022 12:59

Syncona Ltd - London-based healthcare & investment company - Reports quarterly loss for its portfolio company Autolus Therapeutics PLC as research costs rise. Net loss widens to USD42.7 million from USD39.0 million a year ago. Research & development expenses rise to USD34.0 million from USD30.7 million, Syncona explains. Read More

IN BRIEF: Syncona invests GBP15 million more in OMass Therapeutics

28th Apr 2022 12:52

Syncona Ltd - London-based investment company - Invests more into OMass Therapeutics, an Oxford University biotechnology spin-out. After the new GBP15 million investment, Syncona now holds a 31% stake worth GBP44 million in the developer of small molecule drugs. The GBP15 million is part of an oversubscribed GBP75.5 million second round of funding for OMass, which now has raised GBP119 million in total. Read More

Syncona's investee Anaveon receives good trial data

11th Apr 2022 09:25

(Alliance News) - Syncona Ltd on Monday noted that its portfolio company Anaveon AG received "encouraging" first clinical data from its ongoing phase I/II study for ANV419. Read More

Syncona notes portfolio company Freeline annual loss widens in 2021

1st Apr 2022 07:32

(Alliance News) - Syncona Ltd said on Friday that portfolio company Freeline Therapeutics Holdings PLC suffered a widened loss last year. Read More

Syncona to invest further USD20 million in Freeline Therapeutics

11th Mar 2022 08:44

(Alliance News) - Syncona Ltd said on Friday that it agreed to invest USD20.0 million in Freeline Therapeutics Holdings PLC, as part of the investee's USD26.1 million American depositary shares offering. Read More